Stay updated on Nivolumab After SIRT for HCC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab After SIRT for HCC Clinical Trial page.

Latest updates to the Nivolumab After SIRT for HCC Clinical Trial page
- Check5 days agoChange DetectedFooter shows Revision: v3.3.3 and removal of HHS Vulnerability Disclosure and Revision: v3.3.2; this does not affect the trial content, eligibility criteria, or study outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedThese updates pertain to the Publications notes and revision/version information, which are editorial in nature and do not alter study content or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check41 days agoChange DetectedRemoved the government funding status notice; all study details and links remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check55 days agoChange DetectedThe NASIR-HCC study page shows only minor UI adjustments (spacing/formatting) with no changes to study details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check84 days agoChange DetectedMajor update: announces a version upgrade to v3.2.0 and publicly states funding-related operational notices, including that transactions may not be processed until appropriations are enacted.SummaryDifference3%

- Check91 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes provided.SummaryDifference0.1%

Stay in the know with updates to Nivolumab After SIRT for HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab After SIRT for HCC Clinical Trial page.